ReviewDoxil® — The first FDA-approved nano-drug: Lessons learned
Graphical abstract
Doxil vial as sold by Sequus Pharmaceuticals (starting 1996)
Section snippets
What led to Doxil® development: OLV-DOX
Development of Doxil was initiated in Israel and the USA ~ 14 years ago when it became evident in a “first in man” (FIM) clinical trial by Gabizon and Barenholz that a “first generation” liposomal doxorubicin did not justify further clinical development despite an elevation of drug MTD (rev. in [1]). In this FIM trial we used negatively charged, medium-size oligolamellar liposomes (OLV) composed of two low-Tm (fluid) phospholipids [the zwitterionic egg-derived phosphatidylcholine (EPC), the
Liposomal doxorubicin: the desired product profile
We decided that in order for the liposomal doxorubicin product to become an anticancer FDA and EMA approved drug the product should be characterized by the following features:
-
The liposomes used should be at the nano-scale (nano-liposomes) so they will be able to take advantage of the EPR effect and extravasate from the blood vessels at the tumor into the tumor tissue. Such liposomes can be considered as a “Nano-Drug”.
However going nano imposes a major challenge of achieving a sufficient level
Pharmacokinetics and passive targeting to tumors
In our Jerusalem 1991–1994 “first in man Doxil clinical trial” Doxil demonstrated high and selective tumor localization, published in Cancer Research [50]. The data (presented in Fig. 5) are the first proof for the EPR effect induced in tumors by passive targeting in humans [50]. The accumulation of Doxil in humans' tumors was further supported by direct fluorescence microscopy of patient biopsies by Gabizon and coworkers [96].
The above-cited Jerusalem pilot study includes 53 courses of Doxil
Doxil take home lessons and what will next-generation Doxil-like liposomes look like?
In summary, the anticancer nano-drug Doxil shows superiority to free doxorubicin (standard of care) clinical performance in a variety of neoplastic conditions due to its unique EPR-related pharmacokinetics and bio-distribution, which reduce side effects (especially important is the large reduction in cardiac toxicity) and improve overall patient compliance and quality of life. These, when combined with the way the doxorubicin is remote loaded into the long-circulating nano-liposomes, improve
Doxil historical perspectives
Pre-Doxil era (liver passively targeted by liposomal doxorubicin referred to as OLV-DOX)1979 Gabizon and Barenholz started their basic research on liposomal doxorubicin 1984 First clinical trials with liposomal doxorubicin (OLV-DOX which differs to a large extent from Doxil) 1985 LTI licensed the OLV-DOX technology and Barenholz and Gabizon 1990, 1991 I.P. on OLV-DOX 1987 Clinical trial of OLV-DOX failed 1988 Barenholz developed and Yissum, R&D Company of the Hebrew University of Jerusalem, Israel
Doxil I.P. aspects
It is important to note that Doxil® was based on two families of patents. However, there is no direct patent on Doxil. One family covers the transmembrane-driven remote loading of amphipathic weak bases such as doxorubicin [55], [56], while the second deals with contribution of the lipopolymer PEG-DSPE as a lipid component of liposome membrane for prolongation liposome circulation time and RES avoidance [78].
It took ~ 7 1/2 years from the submission of these two families of patent applications in
Generic doxorubicin in liposomes (Doxil-like)
The patent protection of Doxil® in the USA has been over since March 2010, and Doxil/Caelyx is selling well (over $600 million annually), so how come there is still no generic PEGylated liposomal doxorubicin (PLD)-like product approved by the FDA or EMA?
In addition to the complexity of FDA approval of generic Doxil, the current situation is even more complex. Ben Venue Laboratories (the sole supplier) has stopped Doxil production because of FDA-cited GMP deficiencies at their facilities. A
Personal touch
I cannot end this Doxil review without a personal touch. The road to the development of Doxil® covers a major part of my professional career. I have been working on the development of liposomal drugs since 1979. However, I could not perform all my applied multidisciplinary work without the many research years and major efforts I dedicated to basic research in the fields of lipid biochemistry and biophysics. I started to study phospholipid and sphingolipid enzymology when I was a second-year
Special acknowledgments
Professionally, I have a very long list of people to thank, in large part described above. Here, however I would like to thank by name only those people with whom I interacted on Doxil-related matters. Alberto Gabizon, for a 32-year partnership in exciting research including Doxil development, and friendship — the many shared papers and patents with him are excellent evidence of our highly productive collaborative interaction; the late Demetrios (Dimitri) Papahadjopoulos, for his friendship and
References (134)
- et al.
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study
Eur. J. Cancer Clin. Oncol.
(1989) - et al.
The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior
Biochim. Biophys. Acta
(1990) - et al.
In vitro tests to predict in vivo performance of liposomal dosage forms
Chem. Phys. Lipids
(1993) Liposome application: problems and prospects
Curr. Opin. Colloid Interface Sci.
(2001)- et al.
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention
Adv. Drug Deliv. Rev.
(2011) - et al.
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Eur. J. Pharm. Biopharm.
(2009) - et al.
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial
Eur. J. Cancer Clin. Oncol.
(1986) - et al.
Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties
J. Control. Release
(2009) - et al.
Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer
Chem. Phys. Lipids
(2005) - et al.
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases
Biochim. Biophys. Acta
(1993)
Openings between defective endothelial cells explain tumor vessel leakiness
Am. J. Pathol.
The response of fluorescent amines to pH gradients across liposome membranes
Biochim. Biophys. Acta
Catecholamine uptake and concentration by liposomes maintaining pH gradients
Biochim. Biophys. Acta
Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol
Chem. Phys. Lipids
Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery
Biochim. Biophys. Acta
A quantitative model for using acridine orange as a transmembrane pH gradient probe
Anal. Biochem.
Gelation of liposome interior. A novel method for drug encapsulation
FEBS Lett.
In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release
Biochim. Biophys. Acta
Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance
Biochim. Biophys. Acta
Ultrasound triggered release of cisplatin from liposomes in murine tumors
J. Control. Release
Large unilamellar liposomes with low uptake into the reticuloendothelial system
FEBS Lett.
Sterically stabilized liposomes
Biochim. Biophys. Acta
Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation
Chem. Phys. Lipids
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
FEBS Lett.
Liposomes for the sustained drug release in vivo
Biochim. Biophys. Acta
Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
J. Biol. Chem.
PEGylation, successful approach to drug delivery
Drug Discov. Today
Oxidative stress effect on the integrity of lipid bilayers is modulated by cholesterol level of bilayers
Chem. Phys. Lipids
Hydration of polyethylene glycol-grafted liposomes
Biophys. J.
Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies
Biochim. Biophys. Acta
Optimization and upscaling of doxorubicin-containing liposomes for clinical use
J. Pharm. Sci.
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin
Clin. Lymphoma Myeloma
Doxil®—the first FDA-approved nano-drug: from an idea to a product
Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers
Cancer Res.
Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model
Br. J. Cancer
Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration
J. Natl. Cancer Inst.
Design, characterization and anti-tumor activity of adriamycin-containing phospholipid vesicles
Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models
Isr. J. Med. Sci.
Adriamycin-containing liposomes in cancer chemotherapy
Liposome-associated doxorubicin: preclinical pharmacology and exploratory clinical phase
A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors
Proc. Natl. Acad. Sci. U. S. A.
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin
Br. J. Cancer
Quality control assays in the development and clinical use of liposome-based formulations
Stability of liposomal doxorubicin formulations: problems and prospects
Med. Res. Rev.
Rational design of amphiphile-based drug carriers and sterically stabilized carriers
J. Liposome Res.
Relevancy of drug loading to liposomal formulation therapeutic efficacy
J. Liposome Res.
Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles
J. Liposome Res.
Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome
Nanomedicine
Cited by (3239)
Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs
2024, Coordination Chemistry ReviewsUnderstanding the In Vitro-In Vivo Nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin
2024, International Journal of PharmaceuticsA drug delivery strategy emerges that has the potential to transform cancer therapy
2024, Drug Discovery TodayEnhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs
2024, Journal of Colloid and Interface Science